Turner Pope Investor Evening
Integumen is pleased to announce that Gerry Brandon, the Company’s CEO, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd, on Monday 13th May 2019. The event will be held in London, EC2 and will commence at 5pm.
If you want to find out how, in less than 9 months, new management have:
- Cleared over £2m of short and long-term debts beginning with a cash deficit and no credit;
- Eliminated multiple outstanding litigation disputes saving £495,000;
- Increased revenues by 350% in the last 4 months of 2018;
- Bought a company in April 2019 for £3m with growing revenues;
- Placed £2.5m at 300% higher than the lowest share price, since taking over;
- Turned a £1.5m market cap, close to bankruptcy, into a £15m market cap company; and,
- Increased shareholder value by more than 400% from the lowest share price since taking over.
And what all this means for the future of Integumen…
Then register your interest by emailing email@example.com or call on 0203 621 4124
Chief Executive Officer
Gerard is a seasoned international executive and serial entrepreneur, joining Integumen in August 2018. He took over Cellulac as its CEO in May 2012. In 1996 he co-founded, as CEO, Alltracel Pharmaceuticals plc, which completed an IPO on AIM in 2001 and was subsequently acquired in 2008. In 2004 Gerard was appointed Managing Partner for Farmabrand Private Equity. He is an author and Fellow of the Ryan Academy of Entrepreneurs in Dublin.
Big data analytics is key to transforming the future of skin disease drug development which is ranked as the fourth most common cause of human illness. While drug companies still chase molecules for new blockbuster drugs, millions of people are suffering from skin related diseases today.
Revenues grew by 890% to £477,000 (unaudited), combined with revenues for RinoCloud, prior to their acquisition, Group revenues jumped 1,213% to £655,000
Integumen Annual Report at 31 December 2018
Integumen signs 3 contracts and continues to make rapid progress up the value chain by entering into larger contracts for Labskin AI services.
FY 2018 total revenue £502k increased 111% (FY 2017 : £238k);
FY 2018 revenue from continued operations £274k increased 294% (FY 2017 : £93k) following Labskin test kit sales move to full skin-care product test services;
FY 2018 EBITDA losses reduced by 12% to (£1.25m) (FY 2017: (£1.40m))
Launch of Labskin human skin clone tests for Medical Device and Clinical Research trials. Combined with human volunteers doubles number of skin tests possible saving time and money.